ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results
26 mars 2024 16h05 HE
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results
ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call
15 mars 2024 20h01 HE
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
22 févr. 2024 08h30 HE
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024
20 févr. 2024 16h05 HE
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call & Participation at the 36th Annual ROTH Conference in March 2024
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
30 janv. 2024 08h00 HE
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
29 janv. 2024 08h00 HE
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea
08 janv. 2024 08h00 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, welcomes the adoption of...
Data Published by Cureus Journal of Medical Science Shows Successful Treatment of Obstructive Sleep Apnea with ProSomnus Precision Oral Appliance Devices
19 déc. 2023 08h00 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, today announced the publication of a...
ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results
09 nov. 2023 16h17 HE
|
ProSomnus Sleep Technologies, Inc.
ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results
ProSomnus Announces Third Quarter 2023 Investor Call and Business Update
31 oct. 2023 16h05 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), will report its third quarter...